Jiangsu Lianhuan Pharmaceutical (600513.SH) announced that the company recently received the Drug Registration Certificate approved and issued by the National Medical Products Administration (NMPA), for pharmaceutical named moxifloxacin hydrochloride tablets. It is mainly used to treat infections caused by sensitive bacteria in adults (≥18 years old), including acute bacterial sinusitis, acute exacerbations of chronic bronchitis, community-acquired pneumonia, complicated skin and skin tissue infections, complicated intra-abdominal infections, etc.
Zhixun Finance APP News, Jiangsu Lianhuan Pharmaceutical (600513.SH) announced that the company recently received the Drug Registration Certificate approved and issued by the National Medical Products Administration (NMPA), for pharmaceutical named moxifloxacin hydrochloride tablets. It is mainly used to treat infections caused by sensitive bacteria in adults (≥18 years old), including acute bacterial sinusitis, acute exacerbations of chronic bronchitis, community-acquired pneumonia, complicated skin and skin tissue infections, complicated intra-abdominal infections, etc.